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RR = 25.1%; COPD RR = 16%; both RR = 24%). The summary
HRQL score for recipients with both asthma and COPD was
43.8 (p < 0.0001), as compared to 36.4 for the COPD-only and
33.3 for the asthma-only groups. These differences persisted for
each of the 3 subscales, with recipients having both asthma and
COPD experiencing worse HRQL than those with asthma-only
or COPD-only. CONCLUSIONS: Increase in disease severity (as
indicated by the presence of both asthma and COPD as com-
pared to either disease by itself) was associated with statistically
as well as clinically signiﬁcant worsening of HRQL.
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OBJECTIVES: This study examined the persistence and adher-
ence for patients using latanoprost, travoprost, and bimatoprost
across multiple health plans over 12 months. METHODS: Glau-
coma patients were identiﬁed from an employer-based database
covering 1.8 million lives in 40 health plans. Patients with a glau-
coma medical claim and a pharmacy claim for latanoprost,
travoprost, or bimatoprost from September 31, 2001 through
March 31, 2002 were eligible for study entry. Continuous eligi-
bility was required 180 days prior to the index date, deﬁned as
the date of the ﬁrst prescription claim for an ophthalmic drug of
interest, with no evidence of ophthalmic drug use during that
time. These patients were deﬁned as “new therapy starts”. Per-
sistence at 12 months and number of days of adherence was
determined for new starts with at least 3 months of therapy fol-
lowing the index date. Due to potential inconsistencies with days
supply reporting at the pharmacy level, a clinical algorithm was
developed to compute days on therapy. RESULTS: At total of
3822 glaucoma patients were identiﬁed with at least one claim
for latanoprost, travoprost, or bimatoprost. Patients were on
average 73.1 years (SD = 10.1, range = 15–88) and 53.1%
female. A total of 2666 (69.8%) completed the ﬁrst three
months. A total of 70.1% were persistent with therapy at 12
months and were adherent 83.1% of the time. Using the quan-
tity dispensed and the number of days between reﬁlls yielded 8
days of therapy per 1-mL of ophthalmic solution. The mean
number of days on therapy for bimatoprost was signiﬁcantly
greater than latanoprost (p < 0.05). CONCLUSIONS: This ret-
rospective database analysis assessed persistence and adherence
for glaucoma patients using latanoprost, travoprost, and bimato-
prost for 12 months. Although most patients were persistent and
adherent to their therapy for at least 3 months and then at 12
months there may still be opportunities to improve persistence
and adherence with these important ophthalmic therapies.
PES2
MEDICATION ADHERENCE RATES AND DISEASE SEVERITY
CHANGES IN PSORIASIS
Balkrishnan R1, Carroll CL2, Camacho F2, Feldman S2
1University of Texas School of Public Health, Houston,TX, USA;
2Wake Forest University School of Medicine, Winston-Salem, NC,
USA
OBJECTIVE: It is a commonly known fact among physicians
that patients are non-adherent to medication regimens. In der-
matology, there has been little study into the issue of medication
non-adherence. This study examined trends in adherence behav-
ior (measured electronically) to topical medication regimen over
time in patients with psoriasis enrolled in a clinical study. Addi-
tionally, the association between adherence behavior and
changes in severity of psoriasis was explored. METHODS:
Twenty four subjects with psoriasis that were already enrolled in
an 8-week study with salicylic acid and topical tacrolimus oint-
ment combination therapy were given the salicylic acid in a
bottle with the Medication Event Monitoring System (MEMS)
cap. Electronic medication adherence was downloaded from the
cap to a computer at each follow up visit. The primary outcome
was the difference in the change from baseline in the disease
severity (sum score of erythema, scale and thickness scores).
RESULTS: Over the 8 week period the overall adherence rates
declined by 50% from 75.6% to 51%. A signiﬁcant correlation
was found between increased adherence and decreased disease
severity summary score in the ﬁrst week of treatment (Pearson’s
rho = -0.42, p = 0.02), after accounting for treatment effect. This
relationship did not persist after week 1. CONCLUSIONS: The
precipitous decrease in psoriasis medication adherence rates,
even in clinical study settings is cause for concern. Beneﬁts from
these medications may decrease as a result of decreased adher-
ence to prescribed regimens over time.
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OBJECTIVE: Fears of potentially costly use of topical retinoids
for cosmetic treatment of photodamaged skin has resulted in
many managed care organizations placing prior authorization
requirements on this class of medications. The purpose of this
investigation was to examine whether prescribing patterns of a
nationally representative sample of US physicians shed light on
potential inappropriate use of topical retinoids. METHODS: A
retrospective, cross-sectional study of data from the National
Ambulatory Medical Care Survey (1996–2000) was used to
determine the impact of patient diagnosis of acne on the proba-
bility of retinoid prescription were examined in weighted multi-
variate logistic regression models. RESULTS: Topical retinoids
were prescribed in 0.4% of the 3.67 billion visits for any diag-
nosis from 1996–2000, and in nearly 31% of the visits for 38.7
million visits for acne. The study found that there was negligi-
ble prescription of topical retinoids for non-acne related condi-
tions (Risk Ratio [RR] for topical retinoid prescription with acne
diagnosis: 58.8, 95% CI: 33.4, 103.7). This ﬁnding held when
individual retinoids (tretinoin and adapalene) were examined
separately. Clear age-related prescription trends were observed,
with signiﬁcant decrease in prescriptions beyond the teen years.
CONCLUSIONS: The data do not support a need for general
prior authorization of topical retinoids. Prior authorization
requirements for topical retinoids may not be necessary in young
patients, given the very small probability of non-acne related use.
In older patients, prior authorization, if needed at all, should
focus only on those topical retinoids for which there is evidence
of efﬁcacy in treatment of cosmetic photoaging.
